



Clinical trial results:

A Randomized, Double-blind Placebo-controlled and Open-label Active-controlled, Parallel-group, Multicenter, Dose-ranging Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Non-diabetic Severely Obese Subjects

Summary

EudraCT number	2017-003616-39
Trial protocol	SE BE PL
Global end of trial date	08 March 2019

Results information

Result version number	v1 (current)
This version publication date	05 January 2020
First version publication date	05 January 2020

Trial information

Trial identification

Sponsor protocol code	CR108314
-----------------------	----------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03486392
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Janssen Research & Development, LLC
Sponsor organisation address	920 Route 202, Raritan, United States, NJ 08869
Public contact	Clinical Registry Group, Janssen Research & Development, LLC, ClinicalTrialsEU@its.jnj.com
Scientific contact	Clinical Registry Group, Janssen Research & Development, LLC, ClinicalTrialsEU@its.jnj.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	08 March 2019
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	08 March 2019
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The main objective of the study was to assess the effects of JNJ-64565111 compared with placebo in non-diabetic severely obese subjects after 26 Weeks of treatment on the percentage change from baseline in body weight and safety and tolerability.

Protection of trial subjects:

This study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and that are consistent with Good Clinical Practices and applicable regulatory requirements. Safety was evaluated throughout the study and included monitoring of adverse events (AEs), vital sign measurements, clinical laboratory tests (including calcitonin, lipase, amylase, alanine aminotransferase [ALT], aspartate aminotransferase [AST], bilirubin, and sodium), urinalysis, review of concomitant medications, and pregnancy testing.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	26 March 2018
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Belgium: 58
Country: Number of subjects enrolled	Canada: 62
Country: Number of subjects enrolled	United Kingdom: 58
Country: Number of subjects enrolled	Poland: 61
Country: Number of subjects enrolled	Sweden: 81
Country: Number of subjects enrolled	United States: 154
Worldwide total number of subjects	474
EEA total number of subjects	258

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23	0

months)	
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	448
From 65 to 84 years	26
85 years and over	0

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

A total of 474 subjects were randomized out of which 444 subjects completed the study.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

Arms

Are arms mutually exclusive?	Yes
------------------------------	-----

Arm title	Double Blind: Placebo
------------------	-----------------------

Arm description:

Subjects self-administered the matching placebo of JNJ-64565111 subcutaneously (SC) once-weekly throughout the 26-week treatment phase or until early discontinuation of study drug.

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection in pre-filled syringe
Routes of administration	Subcutaneous use

Dosage and administration details:

Subjects self-administered the matching placebo of JNJ-64565111 SC once-weekly.

Arm title	Double Blind: JNJ-64565111 5.0 mg
------------------	-----------------------------------

Arm description:

Subjects self-administered 5.0 milligram (mg) JNJ-64565111 SC once-weekly throughout the 26-week treatment phase or until early discontinuation of study drug.

Arm type	Experimental
Investigational medicinal product name	JNJ-64565111 5.0 mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection in pre-filled syringe
Routes of administration	Subcutaneous use

Dosage and administration details:

Subjects self-administered 5.0 mg JNJ-64565111 SC once-weekly.

Arm title	Double Blind: JNJ-64565111 7.4 mg
------------------	-----------------------------------

Arm description:

Subjects self-administered 7.4 mg JNJ-64565111 SC once-weekly throughout the 26-week treatment phase or until early discontinuation of study drug.

Arm type	Experimental
Investigational medicinal product name	JNJ-64565111 7.4 mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection in pre-filled syringe
Routes of administration	Subcutaneous use

Dosage and administration details:

Subjects self-administered 7.4 mg JNJ-64565111 SC once-weekly.

Arm title	Double Blind: JNJ-64565111 10.0 mg
------------------	------------------------------------

Arm description:

Subjects self-administered 10.0 mg JNJ-64565111 SC once-weekly throughout the 26-week treatment phase or until early discontinuation of study drug.

Arm type	Experimental
Investigational medicinal product name	JNJ-64565111 10.0 mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection in pre-filled syringe
Routes of administration	Subcutaneous use

Dosage and administration details:

Subjects self-administered 10.0 mg JNJ-64565111 SC once-weekly.

Arm title	Open Label: Liraglutide 3.0 mg
------------------	--------------------------------

Arm description:

Subjects self-administered liraglutide at a starting dose of 0.6 mg SC once-daily on Day 1, followed by dose titration up to 1.2, 1.8, 2.4, and 3.0 mg in Weeks 2, 3, 4, and 5 (with 0.6 mg weekly increment up to the full dosage of 3.0 mg by Week 5). Subjects then continued the 3.0 mg once-daily dosage until Week 26 or until early drug discontinuation.

Arm type	Active comparator
Investigational medicinal product name	Liraglutide 3.0 mg
Investigational medicinal product code	
Other name	Saxenda
Pharmaceutical forms	Solution for injection in pre-filled syringe
Routes of administration	Subcutaneous use

Dosage and administration details:

Subjects self-administered liraglutide at a starting dose of 0.6 mg SC once-daily on Day 1, followed by dose titration up to 1.2, 1.8, 2.4, and 3.0 mg in Weeks 2, 3, 4, and 5 (with 0.6 mg weekly increment up to the full dosage of 3.0 mg by Week 5).

Number of subjects in period 1	Double Blind: Placebo	Double Blind: JNJ-64565111 5.0 mg	Double Blind: JNJ-64565111 7.4 mg
Started	60	59	118
Completed	57	59	104
Not completed	3	0	14
Consent withdrawn by subject	3	-	6
Death	-	-	-
Lost to follow-up	-	-	8

Number of subjects in period 1	Double Blind: JNJ-64565111 10.0 mg	Open Label: Liraglutide 3.0 mg
Started	118	119
Completed	109	115
Not completed	9	4
Consent withdrawn by subject	4	1

Death	-	1
Lost to follow-up	5	2

Baseline characteristics

Reporting groups

Reporting group title	Double Blind: Placebo
Reporting group description: Subjects self-administered the matching placebo of JNJ-64565111 subcutaneously (SC) once-weekly throughout the 26-week treatment phase or until early discontinuation of study drug.	
Reporting group title	Double Blind: JNJ-64565111 5.0 mg
Reporting group description: Subjects self-administered 5.0 milligram (mg) JNJ-64565111 SC once-weekly throughout the 26-week treatment phase or until early discontinuation of study drug.	
Reporting group title	Double Blind: JNJ-64565111 7.4 mg
Reporting group description: Subjects self-administered 7.4 mg JNJ-64565111 SC once-weekly throughout the 26-week treatment phase or until early discontinuation of study drug.	
Reporting group title	Double Blind: JNJ-64565111 10.0 mg
Reporting group description: Subjects self-administered 10.0 mg JNJ-64565111 SC once-weekly throughout the 26-week treatment phase or until early discontinuation of study drug.	
Reporting group title	Open Label: Liraglutide 3.0 mg
Reporting group description: Subjects self-administered liraglutide at a starting dose of 0.6 mg SC once-daily on Day 1, followed by dose titration up to 1.2, 1.8, 2.4, and 3.0 mg in Weeks 2, 3, 4, and 5 (with 0.6 mg weekly increment up to the full dosage of 3.0 mg by Week 5). Subjects then continued the 3.0 mg once-daily dosage until Week 26 or until early drug discontinuation.	

Reporting group values	Double Blind: Placebo	Double Blind: JNJ-64565111 5.0 mg	Double Blind: JNJ-64565111 7.4 mg
Number of subjects	60	59	118
Title for AgeCategorical Units: subjects			
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	56	57	111
From 65 to 84 years	4	2	7
85 years and over	0	0	0
Title for AgeContinuous Units: years			
arithmetic mean	46.9	47.3	46.2
standard deviation	± 11.84	± 11.18	± 11.68
Title for Gender Units: subjects			
Female	48	47	86
Male	12	12	32

Reporting group values	Double Blind: JNJ-64565111 10.0 mg	Open Label: Liraglutide 3.0 mg	Total
Number of subjects	118	119	474
Title for AgeCategorical Units: subjects			
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0

Adults (18-64 years)	113	111	448
From 65 to 84 years	5	8	26
85 years and over	0	0	0
Title for AgeContinuous Units: years			
arithmetic mean	46.2	45.6	
standard deviation	± 12.16	± 11.71	-
Title for Gender Units: subjects			
Female	86	89	356
Male	32	30	118

End points

End points reporting groups

Reporting group title	Double Blind: Placebo
Reporting group description: Subjects self-administered the matching placebo of JNJ-64565111 subcutaneously (SC) once-weekly throughout the 26-week treatment phase or until early discontinuation of study drug.	
Reporting group title	Double Blind: JNJ-64565111 5.0 mg
Reporting group description: Subjects self-administered 5.0 milligram (mg) JNJ-64565111 SC once-weekly throughout the 26-week treatment phase or until early discontinuation of study drug.	
Reporting group title	Double Blind: JNJ-64565111 7.4 mg
Reporting group description: Subjects self-administered 7.4 mg JNJ-64565111 SC once-weekly throughout the 26-week treatment phase or until early discontinuation of study drug.	
Reporting group title	Double Blind: JNJ-64565111 10.0 mg
Reporting group description: Subjects self-administered 10.0 mg JNJ-64565111 SC once-weekly throughout the 26-week treatment phase or until early discontinuation of study drug.	
Reporting group title	Open Label: Liraglutide 3.0 mg
Reporting group description: Subjects self-administered liraglutide at a starting dose of 0.6 mg SC once-daily on Day 1, followed by dose titration up to 1.2, 1.8, 2.4, and 3.0 mg in Weeks 2, 3, 4, and 5 (with 0.6 mg weekly increment up to the full dosage of 3.0 mg by Week 5). Subjects then continued the 3.0 mg once-daily dosage until Week 26 or until early drug discontinuation.	

Primary: Percent Change From Baseline in Body Weight at Week 26

End point title	Percent Change From Baseline in Body Weight at Week 26
End point description: Percent change in body weight in kilograms (kg) from baseline to Week 26 was reported. Modified intent-to-treat (mITT) population included all ITT subjects who had taken at least 1 dose of study drug and had at least 1 post-baseline body weight measurement; for liraglutide, only those who titrated to 3.0 mg were included in mITT population. Here 'N' (number of subjects analyzed) signifies number of subjects evaluable for this endpoint.	
End point type	Primary
End point timeframe: Baseline, Week 26	

End point values	Double Blind: Placebo	Double Blind: JNJ-64565111 5.0 mg	Double Blind: JNJ-64565111 7.4 mg	Double Blind: JNJ-64565111 10.0 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	60	58	109	109
Units: Percent Change				
least squares mean (standard error)	-1.76 (± 0.73)	-8.51 (± 0.76)	-9.83 (± 0.56)	-11.80 (± 0.58)

End point values	Open Label: Liraglutide 3.0 mg			
Subject group type	Reporting group			
Number of subjects analysed	108			
Units: Percent Change				
least squares mean (standard error)	-7.54 (\pm 0.54)			

Statistical analyses

Statistical analysis title	Statistical Analysis 1
Comparison groups	Double Blind: Placebo v Double Blind: JNJ-64565111 5.0 mg
Number of subjects included in analysis	118
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Dunnett's method
Parameter estimate	Difference of least square (LS) Means
Point estimate	-6.75
Confidence interval	
level	95 %
sides	2-sided
lower limit	-9.31
upper limit	-4.19
Variability estimate	Standard error of the mean
Dispersion value	1.056

Statistical analysis title	Statistical Analysis 2
Comparison groups	Double Blind: Placebo v Double Blind: JNJ-64565111 7.4 mg
Number of subjects included in analysis	169
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Dunnett's method
Parameter estimate	Difference of LS Means
Point estimate	-8.07
Confidence interval	
level	95 %
sides	2-sided
lower limit	-10.31
upper limit	-5.84
Variability estimate	Standard error of the mean
Dispersion value	0.921

Statistical analysis title	Statistical Analysis 3
-----------------------------------	------------------------

Comparison groups	Double Blind: Placebo v Double Blind: JNJ-64565111 10.0 mg
Number of subjects included in analysis	169
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Dunnett's method
Parameter estimate	Difference of LS Means
Point estimate	-10.04
Confidence interval	
level	95 %
sides	2-sided
lower limit	-12.31
upper limit	-7.78
Variability estimate	Standard error of the mean
Dispersion value	0.934

Statistical analysis title	Statistical Analysis 4
Comparison groups	Double Blind: Placebo v Open Label: Liraglutide 3.0 mg
Number of subjects included in analysis	168
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Dunnett's method
Parameter estimate	Difference of LS Means
Point estimate	-5.78
Confidence interval	
level	95 %
sides	2-sided
lower limit	-7.99
upper limit	-3.57
Variability estimate	Standard error of the mean
Dispersion value	0.91

Primary: Number of Subjects with Treatment Emergent Adverse Events (TEAEs)

End point title	Number of Subjects with Treatment Emergent Adverse Events (TEAEs) ^[1]
-----------------	--

End point description:

An adverse event (AE) is any untoward medical occurrence in a clinical study subject administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non-investigational) product, whether or not related to that medicinal (investigational or non-investigational) product. A TEAE was defined as an AE with an onset after the initiation study drug and before the last study drug date of the double-blind (26-week) treatment phase for plus 28 days for liraglutide subjects, and plus 35 days for JNJ-64565111 and placebo subjects. Safety analysis set included all randomized subjects who had received at least one dose of study drug.

End point type	Primary
----------------	---------

End point timeframe:

Up to Week 30

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Descriptive statistics were done, no inferential statistical analyses were performed.

End point values	Double Blind: Placebo	Double Blind: JNJ-64565111 5.0 mg	Double Blind: JNJ-64565111 7.4 mg	Double Blind: JNJ-64565111 10.0 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	60	59	118	118
Units: Subjects	43	53	110	110

End point values	Open Label: Liraglutide 3.0 mg			
Subject group type	Reporting group			
Number of subjects analysed	119			
Units: Subjects	96			

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects with Greater Than or Equal to (\geq) 5 Percent (%) Body Weight Loss at Week 26

End point title	Number of Subjects with Greater Than or Equal to (\geq) 5 Percent (%) Body Weight Loss at Week 26
-----------------	---

End point description:

Number of subjects with \geq 5% body weight loss from baseline to Week 26 were reported. mITT population included all ITT subjects who had taken at least 1 dose of study drug and had at least 1 post-baseline body weight measurement; for liraglutide, only those who titrated to 3.0 mg were included in mITT population.

End point type	Secondary
----------------	-----------

End point timeframe:

Week 26

End point values	Double Blind: Placebo	Double Blind: JNJ-64565111 5.0 mg	Double Blind: JNJ-64565111 7.4 mg	Double Blind: JNJ-64565111 10.0 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	60	59	116	116
Units: Subjects	8	34	70	62

End point values	Open Label: Liraglutide 3.0			
------------------	-----------------------------	--	--	--

	mg			
Subject group type	Reporting group			
Number of subjects analysed	109			
Units: Subjects	56			

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects with Greater Than or Equal to 10 % Body Weight Loss at Week 26

End point title	Number of Subjects with Greater Than or Equal to 10 % Body Weight Loss at Week 26
-----------------	---

End point description:

Number of subjects with $\geq 10\%$ body weight loss from baseline to Week 26 were reported. mITT population included all ITT subjects who had taken at least 1 dose of study drug and had at least 1 post-baseline body weight measurement; for liraglutide, only those who titrated to 3.0 mg were included in mITT population.

End point type	Secondary
----------------	-----------

End point timeframe:

Week 26

End point values	Double Blind: Placebo	Double Blind: JNJ-64565111 5.0 mg	Double Blind: JNJ-64565111 7.4 mg	Double Blind: JNJ-64565111 10.0 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	60	59	116	116
Units: Subjects	2	23	43	46

End point values	Open Label: Liraglutide 3.0 mg			
Subject group type	Reporting group			
Number of subjects analysed	109			
Units: Subjects	27			

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in Body Weight at Week 26

End point title	Change From Baseline in Body Weight at Week 26
-----------------	--

End point description:

Change from baseline in body weight at Week 26 was reported. mITT population included all ITT subjects who had taken at least 1 dose of study drug and had at least 1 post-baseline body weight measurement; for liraglutide, only those who titrated to 3.0 mg were included in mITT population. Here 'N' (number of subjects analyzed) signifies number of subjects evaluable for this endpoint.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Week 26

End point values	Double Blind: Placebo	Double Blind: JNJ-64565111 5.0 mg	Double Blind: JNJ-64565111 7.4 mg	Double Blind: JNJ-64565111 10.0 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	60	58	109	109
Units: kg				
least squares mean (standard error)	-2.05 (± 0.827)	-9.58 (± 0.861)	-11.07 (± 0.633)	-13.23 (± 0.656)

End point values	Open Label: Liraglutide 3.0 mg			
Subject group type	Reporting group			
Number of subjects analysed	108			
Units: kg				
least squares mean (standard error)	-8.32 (± 0.610)			

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Up to 30 Weeks

Adverse event reporting additional description:

Safety analysis set included all randomized participants who had received at least one dose of study drug.

Assessment type	Non-systematic
-----------------	----------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	21.1
--------------------	------

Reporting groups

Reporting group title	Double Blind: Placebo
-----------------------	-----------------------

Reporting group description:

Subjects self-administered the matching placebo of JNJ-64565111 subcutaneously (SC) once-weekly throughout the 26-week treatment phase or until early discontinuation of study drug.

Reporting group title	Double Blind: JNJ-64565111 5.0 mg
-----------------------	-----------------------------------

Reporting group description:

Subjects self-administered 5.0 milligram (mg) JNJ-64565111 SC once-weekly throughout the 26-week treatment phase or until early discontinuation of study drug.

Reporting group title	Double Blind: JNJ-64565111 7.4 mg
-----------------------	-----------------------------------

Reporting group description:

Subjects self-administered 7.4 mg JNJ-64565111 SC once-weekly throughout the 26-week treatment phase or until early discontinuation of study drug.

Reporting group title	Double Blind: JNJ-64565111 10.0 mg
-----------------------	------------------------------------

Reporting group description:

Subjects self-administered 10.0 mg JNJ-64565111 SC once-weekly throughout the 26-week treatment phase or until early discontinuation of study drug.

Reporting group title	Liraglutide 3.0 mg
-----------------------	--------------------

Reporting group description:

Subjects self-administered liraglutide at a starting dose of 0.6 mg SC once-daily on Day 1, followed by dose titration up to 1.2, 1.8, 2.4, and 3.0 mg in Weeks 2, 3, 4, and 5 (with 0.6 mg weekly increment up to the full dosage of 3.0 mg by Week 5). Subjects then continued the 3.0 mg once-daily dosage until Week 26 or until early drug discontinuation.

Serious adverse events	Double Blind: Placebo	Double Blind: JNJ-64565111 5.0 mg	Double Blind: JNJ-64565111 7.4 mg
Total subjects affected by serious adverse events			
subjects affected / exposed	4 / 60 (6.67%)	3 / 59 (5.08%)	2 / 118 (1.69%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events			
Cardiac disorders			
Myocardial Infarction			
subjects affected / exposed	0 / 60 (0.00%)	0 / 59 (0.00%)	0 / 118 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Stress Cardiomyopathy			
subjects affected / exposed	0 / 60 (0.00%)	0 / 59 (0.00%)	1 / 118 (0.85%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pregnancy, puerperium and perinatal conditions			
Abortion Spontaneous			
subjects affected / exposed	0 / 60 (0.00%)	1 / 59 (1.69%)	0 / 118 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Ileus			
subjects affected / exposed	0 / 60 (0.00%)	1 / 59 (1.69%)	0 / 118 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis Acute			
subjects affected / exposed	0 / 60 (0.00%)	0 / 59 (0.00%)	0 / 118 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Umbilical Hernia			
subjects affected / exposed	1 / 60 (1.67%)	0 / 59 (0.00%)	0 / 118 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	0 / 60 (0.00%)	0 / 59 (0.00%)	1 / 118 (0.85%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Menorrhagia			
subjects affected / exposed	1 / 60 (1.67%)	0 / 59 (0.00%)	0 / 118 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Biliary Colic			

subjects affected / exposed	0 / 60 (0.00%)	1 / 59 (1.69%)	0 / 118 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholelithiasis			
subjects affected / exposed	0 / 60 (0.00%)	0 / 59 (0.00%)	0 / 118 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Major Depression			
subjects affected / exposed	0 / 60 (0.00%)	0 / 59 (0.00%)	0 / 118 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Osteoarthritis			
subjects affected / exposed	1 / 60 (1.67%)	0 / 59 (0.00%)	0 / 118 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Pneumonia			
subjects affected / exposed	0 / 60 (0.00%)	0 / 59 (0.00%)	0 / 118 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	0 / 60 (0.00%)	0 / 59 (0.00%)	0 / 118 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyponatraemia			
subjects affected / exposed	0 / 60 (0.00%)	0 / 59 (0.00%)	0 / 118 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Obesity			

subjects affected / exposed	1 / 60 (1.67%)	0 / 59 (0.00%)	0 / 118 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Double Blind: JNJ-64565111 10.0 mg	Liraglutide 3.0 mg	
Total subjects affected by serious adverse events			
subjects affected / exposed	4 / 118 (3.39%)	4 / 119 (3.36%)	
number of deaths (all causes)	0	1	
number of deaths resulting from adverse events			
Cardiac disorders			
Myocardial Infarction			
subjects affected / exposed	0 / 118 (0.00%)	1 / 119 (0.84%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Stress Cardiomyopathy			
subjects affected / exposed	0 / 118 (0.00%)	0 / 119 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pregnancy, puerperium and perinatal conditions			
Abortion Spontaneous			
subjects affected / exposed	0 / 118 (0.00%)	0 / 119 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Ileus			
subjects affected / exposed	0 / 118 (0.00%)	0 / 119 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatitis Acute			
subjects affected / exposed	0 / 118 (0.00%)	1 / 119 (0.84%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Umbilical Hernia			

subjects affected / exposed	0 / 118 (0.00%)	0 / 119 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vomiting			
subjects affected / exposed	2 / 118 (1.69%)	0 / 119 (0.00%)	
occurrences causally related to treatment / all	2 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Reproductive system and breast disorders			
Menorrhagia			
subjects affected / exposed	0 / 118 (0.00%)	0 / 119 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatobiliary disorders			
Biliary Colic			
subjects affected / exposed	0 / 118 (0.00%)	1 / 119 (0.84%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholelithiasis			
subjects affected / exposed	0 / 118 (0.00%)	1 / 119 (0.84%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychiatric disorders			
Major Depression			
subjects affected / exposed	0 / 118 (0.00%)	1 / 119 (0.84%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			
Osteoarthritis			
subjects affected / exposed	0 / 118 (0.00%)	0 / 119 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Pneumonia			

subjects affected / exposed	1 / 118 (0.85%)	0 / 119 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	1 / 118 (0.85%)	0 / 119 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyponatraemia			
subjects affected / exposed	1 / 118 (0.85%)	0 / 119 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Obesity			
subjects affected / exposed	0 / 118 (0.00%)	0 / 119 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Double Blind: Placebo	Double Blind: JNJ-64565111 5.0 mg	Double Blind: JNJ-64565111 7.4 mg
Total subjects affected by non-serious adverse events			
subjects affected / exposed	33 / 60 (55.00%)	43 / 59 (72.88%)	106 / 118 (89.83%)
Investigations			
Hepatic Enzyme Increased			
subjects affected / exposed	0 / 60 (0.00%)	0 / 59 (0.00%)	2 / 118 (1.69%)
occurrences (all)	0	0	2
Nervous system disorders			
Dysgeusia			
subjects affected / exposed	1 / 60 (1.67%)	4 / 59 (6.78%)	3 / 118 (2.54%)
occurrences (all)	1	4	3
Headache			
subjects affected / exposed	6 / 60 (10.00%)	7 / 59 (11.86%)	20 / 118 (16.95%)
occurrences (all)	10	10	31
General disorders and administration site conditions			

Fatigue			
subjects affected / exposed	2 / 60 (3.33%)	7 / 59 (11.86%)	15 / 118 (12.71%)
occurrences (all)	2	7	20
Injection Site Bruising			
subjects affected / exposed	4 / 60 (6.67%)	2 / 59 (3.39%)	1 / 118 (0.85%)
occurrences (all)	5	2	1
Gastrointestinal disorders			
Abdominal Discomfort			
subjects affected / exposed	1 / 60 (1.67%)	3 / 59 (5.08%)	0 / 118 (0.00%)
occurrences (all)	1	3	0
Abdominal Distension			
subjects affected / exposed	2 / 60 (3.33%)	4 / 59 (6.78%)	6 / 118 (5.08%)
occurrences (all)	2	4	6
Abdominal Pain			
subjects affected / exposed	1 / 60 (1.67%)	2 / 59 (3.39%)	8 / 118 (6.78%)
occurrences (all)	1	2	8
Abdominal Pain Upper			
subjects affected / exposed	2 / 60 (3.33%)	2 / 59 (3.39%)	10 / 118 (8.47%)
occurrences (all)	2	2	10
Constipation			
subjects affected / exposed	3 / 60 (5.00%)	7 / 59 (11.86%)	20 / 118 (16.95%)
occurrences (all)	5	9	23
Diarrhoea			
subjects affected / exposed	3 / 60 (5.00%)	8 / 59 (13.56%)	24 / 118 (20.34%)
occurrences (all)	5	14	32
Dry Mouth			
subjects affected / exposed	1 / 60 (1.67%)	4 / 59 (6.78%)	6 / 118 (5.08%)
occurrences (all)	1	4	10
Dyspepsia			
subjects affected / exposed	2 / 60 (3.33%)	5 / 59 (8.47%)	18 / 118 (15.25%)
occurrences (all)	2	5	19
Eructation			
subjects affected / exposed	0 / 60 (0.00%)	4 / 59 (6.78%)	14 / 118 (11.86%)
occurrences (all)	0	4	15
Gastrooesophageal Reflux Disease			

subjects affected / exposed occurrences (all)	1 / 60 (1.67%) 1	5 / 59 (8.47%) 5	13 / 118 (11.02%) 13
Nausea subjects affected / exposed occurrences (all)	4 / 60 (6.67%) 6	30 / 59 (50.85%) 42	80 / 118 (67.80%) 181
Vomiting subjects affected / exposed occurrences (all)	0 / 60 (0.00%) 0	12 / 59 (20.34%) 18	47 / 118 (39.83%) 118
Infections and infestations Gastroenteritis subjects affected / exposed occurrences (all)	3 / 60 (5.00%) 3	1 / 59 (1.69%) 1	1 / 118 (0.85%) 1
Nasopharyngitis subjects affected / exposed occurrences (all)	9 / 60 (15.00%) 13	5 / 59 (8.47%) 5	11 / 118 (9.32%) 11
Pharyngitis subjects affected / exposed occurrences (all)	3 / 60 (5.00%) 3	0 / 59 (0.00%) 0	2 / 118 (1.69%) 2
Upper Respiratory Tract Infection subjects affected / exposed occurrences (all)	3 / 60 (5.00%) 4	0 / 59 (0.00%) 0	4 / 118 (3.39%) 5
Urinary Tract Infection subjects affected / exposed occurrences (all)	3 / 60 (5.00%) 3	4 / 59 (6.78%) 4	10 / 118 (8.47%) 12
Metabolism and nutrition disorders Decreased Appetite subjects affected / exposed occurrences (all)	1 / 60 (1.67%) 1	10 / 59 (16.95%) 10	16 / 118 (13.56%) 18

Non-serious adverse events	Double Blind: JNJ-64565111 10.0 mg	Liraglutide 3.0 mg	
Total subjects affected by non-serious adverse events subjects affected / exposed	104 / 118 (88.14%)	81 / 119 (68.07%)	
Investigations Hepatic Enzyme Increased subjects affected / exposed occurrences (all)	6 / 118 (5.08%) 6	0 / 119 (0.00%) 0	
Nervous system disorders			

Dysgeusia subjects affected / exposed occurrences (all)	2 / 118 (1.69%) 2	0 / 119 (0.00%) 0	
Headache subjects affected / exposed occurrences (all)	8 / 118 (6.78%) 9	9 / 119 (7.56%) 10	
General disorders and administration site conditions			
Fatigue subjects affected / exposed occurrences (all)	17 / 118 (14.41%) 17	5 / 119 (4.20%) 6	
Injection Site Bruising subjects affected / exposed occurrences (all)	2 / 118 (1.69%) 2	1 / 119 (0.84%) 2	
Gastrointestinal disorders			
Abdominal Discomfort subjects affected / exposed occurrences (all)	3 / 118 (2.54%) 3	1 / 119 (0.84%) 1	
Abdominal Distension subjects affected / exposed occurrences (all)	6 / 118 (5.08%) 7	7 / 119 (5.88%) 9	
Abdominal Pain subjects affected / exposed occurrences (all)	4 / 118 (3.39%) 5	3 / 119 (2.52%) 3	
Abdominal Pain Upper subjects affected / exposed occurrences (all)	3 / 118 (2.54%) 3	8 / 119 (6.72%) 8	
Constipation subjects affected / exposed occurrences (all)	21 / 118 (17.80%) 26	20 / 119 (16.81%) 24	
Diarrhoea subjects affected / exposed occurrences (all)	23 / 118 (19.49%) 37	27 / 119 (22.69%) 36	
Dry Mouth subjects affected / exposed occurrences (all)	5 / 118 (4.24%) 5	3 / 119 (2.52%) 3	
Dyspepsia			

subjects affected / exposed	13 / 118 (11.02%)	9 / 119 (7.56%)	
occurrences (all)	15	9	
Eructation			
subjects affected / exposed	16 / 118 (13.56%)	5 / 119 (4.20%)	
occurrences (all)	36	5	
Gastrooesophageal Reflux Disease			
subjects affected / exposed	12 / 118 (10.17%)	9 / 119 (7.56%)	
occurrences (all)	14	12	
Nausea			
subjects affected / exposed	79 / 118 (66.95%)	48 / 119 (40.34%)	
occurrences (all)	146	74	
Vomiting			
subjects affected / exposed	65 / 118 (55.08%)	20 / 119 (16.81%)	
occurrences (all)	108	38	
Infections and infestations			
Gastroenteritis			
subjects affected / exposed	1 / 118 (0.85%)	1 / 119 (0.84%)	
occurrences (all)	1	1	
Nasopharyngitis			
subjects affected / exposed	6 / 118 (5.08%)	10 / 119 (8.40%)	
occurrences (all)	10	10	
Pharyngitis			
subjects affected / exposed	0 / 118 (0.00%)	3 / 119 (2.52%)	
occurrences (all)	0	3	
Upper Respiratory Tract Infection			
subjects affected / exposed	2 / 118 (1.69%)	6 / 119 (5.04%)	
occurrences (all)	3	6	
Urinary Tract Infection			
subjects affected / exposed	7 / 118 (5.93%)	5 / 119 (4.20%)	
occurrences (all)	9	5	
Metabolism and nutrition disorders			
Decreased Appetite			
subjects affected / exposed	20 / 118 (16.95%)	10 / 119 (8.40%)	
occurrences (all)	20	11	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported